53results about How to "Lessen kidney damage" patented technology

The invention discloses a hemoglobin-based oxygen carrier, which comprises hemoglobin, haptoglobin and polyethyleneglycol-polyester nanoparticles. Hemoglobin is connected on the surfaces of the polyethyleneglycol-polyester nanoparticles by haptoglobin. The hemoglobin-based oxygen carrier provided by the invention has no obvious toxicity on the cells, the blood plasma does not have obvious free hemoglobin in the blood plasma after the hemoglobin-based oxygen carrier is infused, and no hypertension reaction is produced, so that the defect that the traditional hemoglobin-based oxygen carrier is high in side effects is overcome. The hemoglobin-based oxygen carrier has a good application prospect and a economic benefit.

The invention provides a traditional Chinese medicine composition for treating primary nephrotic syndrome. The traditional Chinese medicine composition comprises the following active pharmaceutical ingredients: membranous milkvetch root, liquorice root, epimedium herb, medicinal Indianmulberry root, flastem milkvetch seed, sappan wood, cowherb seed, zedoary tumeric, common anemarrhena rhizome, amur corktree bark, barbed skullcap herb, radix salviae miltiorrhizae, rice bean, common yam rhizome, manyprickle acanto-panax root, gordon euryale seed, rhizome, sharpleaf galangal fruit, fourstamen stephania root, walnut kernel, glabrous greenbrier rhizome, sinkiang arnebia root, sevenlobed yam rhizome, cochinchnese asparagus root, belvedere fruit, medcinal evodia fruit, lychee seed, dendrobium, glossy privet fruit and Chinese angelica. The traditional Chinese medicine composition provided by the invention is used for treating the primary nephrotic syndrome, can antagonize the side effects of hormones and other Western medicines, improve the blood flow of kidney, reduce urine proteins, retard kidney damages, improve the hypercoagulable state of a patient, consolidate efficacy, reduce the rebound phenomenon of the disease and realize few side effects, low recurrence rate and high complete relief rate, and has a certain efficacy for treating the primary nephrotic syndrome.

The invention relates to a capsule for clearing away turbid and tonifying kidneys. The capsule is prepared from the following raw materials by weight: 100g of cordyceps sinensis, 1400g of astragalus membranaceus, 280g of root of red-rooted salvia, 280g of flowers carthami, 280g of spina date seeds, 500g of semen cuscutae and 100g of rheum officinale. The applied capsule for clearing away turbid and tonifying the kidneys is used for treating both deficiency and excess and treating both symptoms and root causes, is accurate in curative effect, rigorous in formula, and simple and convenient to prepare, and has a broad application prospect.

The invention relates to a schisandra chinensis-oyster dealcoholic liver-protecting health medicine and a preparation method thereof. According to the invention, schisandra chinensis and oyster are adopted in compatibility and prepared into a health medicine with dealcoholic and liver-protecting main effects, and oyster extract taken as a major medicine, schisandra chinensis extract, microcrystal cellulose, a filling agent, CMS-Na, an internal disintegrating agent, a water wetter and talcum powder are prepared into the schisandra chinensis-oyster dealcoholic liver-protecting health medicine. Excessive drinking can do a certain harm to health, so that definite effects of the schisandra chinensis-oyster dealcoholic liver-protecting health medicine on multiple complications, such as hepatic damage, cardia-cerebrovascular diseases, stomachache, obesity and hyperlipemia, of alcoholism need to be contained; and the schisandra chinensis-oyster dealcoholic liver-protecting health medicine adopts schisandra chinensis and oyster and also pays attention to concomitant symptoms of drinking, so that the aim of relieving both primary and secondary symptoms is achieved.

The invention discloses an oxygen carrier based on a hemoglobin-haptoglobin compound and a preparation method of the oxygen carrier. The oxygen carrier comprises haptoglobin, hemoglobin, antioxidant and pyridoxal phosphate. The hemoglobin-haptoglobin compound is formed as a unit for bringing the oxygen carrying activity into play by virtue of special combination ability of the haptoglobin and the hemoglobin. The oxygen carrier based on the hemoglobin-haptoglobin compound disclosed by the invention is free of hypertension reaction after being infused, and capable of protecting an isolated heart. And therefore, the oxygen carrier can be used for clinical blood transfusion, protecting vital organs including the heart and the like from ischemia reperfusion injuries, and has good application prospects and economical benefits.

The invention relates to application of oleanolic acid in preparation of drugs for treatment autoimmune diseases, and belongs to the technical field of biomedicine. The oleanolic acid can inhibit thefunction of the transcription factor ROR[gamma]t, inhibit the differentiation of Th17 cells, and inhibit the transcriptional expression of the target genes IL-17A and IL-17F of ROR[gamma]t at the RNAlevel, and inhibit IL-17A cytokines. The secretion inhibits the level of anti-dsDNA antibodies in the serum; the oleanolic acid of the present invention has an obvious Th17 cell activity inhibitory function, and provides a lead structure for the development of new drugs for the treatment of autoimmune diseases.

The invention belongs to the field of biopharmacology, and relates to a purpose of hydrogen gas to preparation of renal fibrosis treatment medicine, in particular to a purpose of hydrogen gas to preparation of medicine for treating renal fibrosis caused by chronic nephrosis. A built animal model is subjected to biochemical index detection, isolated cell study, western blotting experiments, immunohistochemistry and data analysis after hydrogen gas intervening; the result shows that the hydrogen gas can realize the fibrosis inhibition on the pathological environment induction through an sirt1 path; the harm to the renal function unit in the fibrosis process is reduced through improving the sirt1; and the hydrogen gas can be further used for preparing a medicine preparation for treating renalfibrosis, particularly the renal fibrosis caused by chronic nephrosis.

The invention relates to ethanol extracting solution of desmodium renifolium and an application thereof and belongs to the field of medicines. The ethanol extracting solution has the beneficial effects that the desmodium renifolium as a Dai medicine has an effect of preventing and treating chronic renal failure, and the mechanism is associated with improvement of renal anemia of a rat with chronicrenal failure and reduction of renal injury and renal interstitial fibrosis degree. The invention provides an application direction of the desmodium renifolium, the ethanol extracting solution and water extracting solution thereof in preventing and treating the chronic renal failure, provides a preparation method of desmodium renifolium tablets and provides pharmacodynamic basis for further research and development of the desmodium renifolium tablets.

The invention discloses a pharmaceutical composition for treating chronic nephritis. The pharmaceutical composition is prepared from the following raw materials: fructus schizandrae, rhizoma chuanxiong, astragalus, epimedium, glossy privet fruit, poria cocos, dandelion, herba houttuyniae, cortex magnoliae officinalis, semen lablab album, campsis grandiflora, cassia twig, fructus aurantii immaturus, spreading hedyotis herb, rhizoma imperatae, cortex mori radicis, salviae miltiorrhizae, semen ziziphi spinosae, semen cuscutae, atractylodes lancea, rhizoma alismatis, monkshood, radix glycyrrhizae and peach seeds. The pharmaceutical composition disclosed by the invention is strict in components, simple and convenient in preparation, exact in curative effective of treating chronic nephritis and wide in prospect.

The invention relates to a medicine composition for treating nephropathy. The medicine is prepared from herba epimedii, frangrant ainsliaea herb, polygonum multiflorum, honeysuckle, myrrh, dandelions, oriental wormwood, coptis chinensis, the root of kudzu vines, teasel roots, the root of bidentate achyranthes, radix stemonae, cinnamon, rhizoma atractylodis, radix paeoniae alba, Chinese yams, ginkgo leaves, burdock, rohdea japonica, pepper, acanthopanax, rhizoma acori graminei, golden cypress, rhizoma alismatis and peach kernels. The medicine composition treats both symptoms and root causes of chronic nephrosis in a deficiency and excess mode, the curative effect is definite, the formulation is precise, preparation is easy and convenient, and broad application prospects are achieved.

The invention relates to a novel medicine application of human urinary kallidinogenase, i.e. the application of the human urinary kallidinogenase in preparing medicine for treating diabetic nephropathy.

Methods for reducing kidney damage induced by radiographic contrast medium or another nephrotoxic drug or substance administered to a patient include reducing the temperature of the patient by positioning an endovascular heat exchange device in a blood vessel of the patient and adjusting the temperature of the device to cause a reduction in the patient's temperature. The patient's temperature may be reduced prior to, during, and/or after, the administration of the contrast medium. The methods may also include administering an anti-shivering mechanism to the patient to reduce shivering caused by the reduction in the patient's temperature. The methods may also include disrupting the laminarity of blood flow around the device to enhance the temperature exchange between the device and the blood flowing around the device. The endovascular heat exchange device may be an endovascular heat exchange catheter. The device may be a component of a system, which includes a temperature controller in communication with the endovascular heat exchange device to reduce the temperature of the patient to reduce the temperature of the patient's kidneys.

The invention relates to a medicine preparation for treating chronic nephrosis. The medicine preparation is prepared from the following raw materials: epimedium, obovate ainsliaea, polygonum multiflorum, lonicera japonica, myrrh, dandelion, herba artemisiae scopariae, coptis chinensis, kudzu vine root, radix dipsaci, radix achyranthis bidentatae, radix stemonae, cinnamon, rhizoma atractylodis, radix paeoniae alba, Chinese yam, gingko leaves, burdock, rohdea japonica, pepper, manyprickle acanthopanax root, rhizoma acori graminei, cortex phellodendri, rhizoma alismatis and peach kernels. The medicine preparation can be used for treating both symptoms and root causes of chronic nephrosis, has the advantages of exact curative effect, strict prescription and convenient preparation, and has a wide application prospect.

The invention relates to the technical field of electronic nephroscopes, and discloses a flexible electronic nephroscope with a bendable tail end, the flexible electronic nephroscope comprises a nephroscope body, a light source and a camera shooting integrated system, the light source and the camera shooting integrated system are matched with the nephroscope body, the nephroscope body comprises a nephroscope pipe and a handle nephroscope operation part, the nephroscope pipe comprises a main hose, and the left end of the main hose is fixedly connected with a bending part protection pipe; a bending assembly is arranged in the bending part protection pipe, a control mechanism used for controlling the bending assembly is arranged in the handle operation part, the bending assembly comprises a bending snake bone, the left end and the right end of the bending snake bone are fixedly connected with a left end piece and a right end piece respectively, and a turning wheel is driven to rotate by shifting a corner knob. According to the flexible electronic nephroscope with the bendable tail end, the flexible steel wire can pull one end of the left end piece, the bent snake bone drives the nephroscope pipe to be bent, the active bending part of the nephroscope pipe is bent in the front direction and the back direction, the bending angle is 200 +/-10 degrees, bending is free of damping, the nephroscope can conveniently reach the renal pelvis and all renal calyces, and no dead angle is left for stone breaking and removing.

The invention relates to a traditional Chinese medicine brown ginseng preparation for anti-tumor assistant treatment, which includes, by weight, 270-330 g of brown ginseng, 30-80 g of astragalus membranaceus, 70-130 g of panax-notoginseng, 80-120 g of ground beetles, 30-50 g of pericarpium citri reticulatae, 70-130 g of radix bupleuri, 90-110 g of lotus seed extract, and 80-120 g of lucid ganoderma. The brown ginseng is produced in Fusong of the northeast and is mainly planted in low mountains being lower than 300-800 m in elevation. The brown ginseng is suitable for annual average temperatureof 2.4-13.9 DEG C and loves cold and wet weathers. The brown ginseng preparation is simple in preparation method and has no toxic and side effects, can effectively improve postoperative recovery of tumor patient, improves immunity and has inhibition effect on tumors. By replication of an malignant tumor animal model and supplement of pharmacodynamics and toxicologic informations of tumor immunotherapy of special-purpose ginseng polysaccharides and saponins, the preparation can supply evidence for tumor assistant treatment.

The invention relates to a pharmaceutical composition containing ceftizoxime sodium and pediatric compound amino acid injection (19AA-I), in particular to a combined application package. The pharmaceutical composition contains ceftizoxime sodium and pediatric compound amino acid injection (19AA-I). Compared with the matching and mixing use of ceftizoxime sodium and pediatric compound amino acid injection (19AA-I), the combined application package has the advantages that the steps are simplified, the pediatric medication security is improved, the stability of ceftizoxime sodium is greatly facilitated, and the clinical application quality and bioavailability of the medicine can be improved.